Lee Sang-hoon (#3285)
- $ 1 B
- Biotech
- United States
- M
- 63 Years
'A form of double taxation': Are management fees on new houses quietly getting out of control?
Trump Official Blames Biden Admin for Economic ‘Mess’ — As Resurfaced Clip Shows Him Saying Trump Would Own the Economy By 2026
Is Precigen, Inc. (PGEN) A Good Stock To Buy Now?
Is Transocean Ltd. (RIG) A Good Stock To Buy Now?
Tesla is selling Chinese-made cars in Canada to escape the tariffs that both China and America imposed on it
Insecurity didn’t start with Tinubu, group defends president’s security record
Vibrating pillow sleeve warns deaf sleepers of burglars and fires
How Kepler built verifiable AI for financial services with Claude
Is ASML Holding N.V. (ASML) A Good Stock To Buy Now?
5-Letter Words Ending in ‘Y’ to Help You Improve Your Wordle Skills
About Me
Lee Sang-hoon is the founder, chairman, CEO and chief research officer of South Korean biotechnology company ABL Bio. ABL Bio develops bispecific antibodies, which target two molecules simultaneously to improve treatment outcomes for cancer and neurodegenerative diseases. In November 2025, it signed a $2.6 billion technology-transfer deal with Eli Lilly related to ABL Bio's Grabody-B blood-brain-barrier-penetrating bispecific antibody technology. Lee founded ABL Bio in 2016 and listed it on Korea's Kosdaq stock exchange two years later.
Achievements
Career Highlights
A snapshot of the defining milestones, leadership decisions, and breakthroughs that shaped Lee Sang-hoon’s rise and global influence.
Wealth Growth
Net Worth Growth Over Time
Tracking Lee Sang-hoon’s net worth journey over the years, highlighting key growth phases and financial milestones.
© Iconic Billionaires